Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
Gϋnter von Minckwitz(German Breast group), Fabio Puglisi(University of Udine), Javier Cortés(Vall d'Hebron Hospital Universitari), Eduard Vrdoljak(University of Split), Norbert Marschner(University Medical Center Freiburg), Christoph Zielinski(Comprehensive Cancer Center Vienna), Cristian Villanueva(Centre Hospitalier Universitaire de Besançon), Gilles Romieu(Institut de Recherche en Cancérologie de Montpellier), István Láng(National Institute of Oncology), Eva Ciruelos(Hospital Universitario 12 De Octubre), Michele De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Corinne Veyret(Centre Henri Becquerel), Sabine de Ducla(Roche (Switzerland)), Ulrich Freudensprung(Roche (Switzerland)), Stefanie Srock(Roche (Switzerland)), Joseph Gligorov(Sorbonne Université)
Cited by 145
Abstract
Related Papers
No related papers found
Powered by citation graph analysis